NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Last trade$0.7906
Day change-$0.0009 (-0.11%)
Day range$0.752 – $0.808
Volume671,176
Market cap$92M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for NBP.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for NBP.
Recent news
Company coverage with links to the original publishers.
NovaBridge Biosciences announced updated Phase 1b data for givastomig, a CLDN18.2 x 4-1BB bispecific antibody, showing an objective response rate of 79% and median progression-free survival of 16.9 months in first-line metastatic gastroesophageal adenocarcinoma. The company selected the 8 mg/kg dose for registrational development with FDA alignment on Phase 3 study design, supported by Orphan Drug and Fast Track Designations.
NovaBridge Biosciences announced the appointment of Martin Dewhurst, a veteran healthcare executive with over 30 years of experience, to its Board of Directors as an independent director and member of both the Audit and Compensation Committees. Dewhurst brings extensive governance and strategic expertise from his tenure at McKinsey & Company and multiple board positions across biotech, biopharma, and healthcare companies.
NovaBridge Biosciences announced its annual general meeting of shareholders will be held on September 8, 2026, at its Shanghai office. The company, a clinical-stage biopharmaceutical firm, is advancing innovative medicines including givastomig for gastric cancer and VIS-101 for retinal vascular diseases. Shareholders of record as of July 27, 2026, are entitled to attend and vote.
NovaBridge Biosciences announced its inclusion in the Nasdaq Biotech Index effective December 19, 2025, and will ring the Nasdaq opening bell on January 2, 2026. The company highlighted this milestone as recognition of its strategic vision and pipeline strength as a global biotechnology platform focused on developing innovative medicines.
NovaBridge Biosciences and ABL Bio reported positive Phase 1 dosing study results for ragistomig, a 4-1BB X PD-L1 bispecific antibody designed to treat patients resistant to checkpoint inhibitors, with extended dosing interval showing strong anti-tumor efficacy and improved safety profile.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.